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Article 5.1 of Council Decision 2005/387/JHA (1) (hereinafter referred to as the ‘Decision’) 
stipulates that ‘Where Europol and the EMCDDA, or the Council, acting by a majority of its 
members, consider that the information provided by the Member State on a new psychoactive 
substance merits the collection of further information, this information shall be collated and 
presented by Europol and the EMCDDA in the form of a Joint Report (hereinafter the ‘Joint Report’).’ 
The Joint Report shall be submitted to the Council, the European Medicines Agency (EMA) (2) and 
the Commission.
At the end of September 2012, the EMCDDA and Europol examined the available information on 
a new psychoactive substance 5-(2-aminopropyl)indole (commonly known by the abbreviation 
‘5-IT’), through a joint assessment based upon the following criteria:
1. the amount of the material seized;
2. evidence of organised crime involvement;
3. evidence of international trafficking;
4. analogy with better-studied compounds;
5. evidence of the potential for further (rapid) spread; and,
6. evidence of cases of serious intoxication or fatalities.
The EMCDDA and Europol agreed that the information collected on 5-(2-aminopropyl)indole 
satisfied criteria 1, 4, 5 and 6. The two organisations therefore concluded that sufficient information 
had been accumulated to merit the production of a Joint Report on 5-(2-aminopropyl)indole as 
stipulated by Article 5.1 of the Decision.
(1) OJ L 127, 20.5.2005, p. 32.
(2) Formerly referred to as the EMEA.
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2. Information collection process
In compliance with the provisions of the Decision, on 3 October 2012 the EMCDDA and Europol 
launched a procedure for the collection of information on 5-(2-aminopropyl)indole, in order to 
prepare the Joint Report. The information was collected mainly through the Reitox national focal 
points in the Member States and Croatia, Turkey and Norway as well as the Europol National 
Units. In addition, the EMA collected information through the Member States’ national competent 
authorities responsible for human and veterinary medicinal products. The information collection 
process was largely concluded by 14 November 2012; however, additional information and 
clarifications from some countries were received up to four weeks after this date.
Europol asked the Europol National Units to provide information on:
•  the level of production of 5-(2-aminopropyl)indole in their country;
•  the level of distribution of 5-(2-aminopropyl)indole in their country;
•  the level of trafficking of 5-(2-aminopropyl)indole in their country, both for internal, transit or 
export purposes;
•  the number of seizures of 5-(2-aminopropyl)indole in their country, the total amount of the 
seizures, country of origin, details on the physical forms (including photos);
•  the role of organised crime, or criminal groups, in the production, distribution and trafficking of 
5-(2-aminopropyl)indole in their country; and,
•  any known aspect of violence and/or money laundering relating to the production and 
trafficking of 5-(2-aminopropyl)indole.
Europol received responses from 22 Member States and Norway.
According to Article 5.3 of the Decision, the EMA asked the Member States’ national competent 
authorities responsible for human and veterinary medicinal products to provide information on whether:
•  the new psychoactive substance 5-(2-aminopropyl)indole has obtained a marketing authorisation;
•  the new psychoactive substance 5-(2-aminopropyl)indole is the subject of an application for a 
marketing authorisation; and,
•  a marketing authorisation that had been granted in respect of the new psychoactive substance 
5-(2-aminopropyl)indole has been suspended.
17 Member States, Iceland and Norway replied to the EMA’s request regarding human and/or 
veterinary medicinal products.
Furthermore, in anticipation of Article 7.3 of the Decision in relation to the manufacturing of 
medicinal products in the European Union, the EMA also requested whether the new psychoactive 
substance 5-(2-aminopropyl)indole is used to manufacture a medicinal product:
75-(2-aminopropyl)indole
•  which has been granted a marketing authorisation;
•  for which an application has been made for a marketing authorisation; and,
•  for which a marketing authorisation has been suspended by a competent authority.
The same 17 Member States, Iceland and Norway replied to the EMA’s request in this regard.
A list of the information sources used to inform the Joint Report are listed in Annex 1, and include 
data collected by the EMCDDA through:
1.  a structured questionnaire from the Reitox national focal points. The EMCDDA received replies 
from 27 Member States as well as Croatia, Norway and Turkey;
2.  a specific information request to the World Health Organization on whether or not 
5-(2-aminopropyl)indole is under assessment by the United Nations system (see section 3.5); and,
3.  a structured literature review that included a chemical sub-structure search and Internet search.
Thus, information included in sections 3.2.1 and 3.3 of the Joint Report was provided by Europol, 
while the EMCDDA provided information included in sections 3.1, 3.2.2, 3.4, 3.5, 3.6, 3.7, 
3.8.1, 3.8.2 and 3.8.3 (partly). The information included in sections 3.4.1 (partly), 3.8.3 (partly), 
4.1, 4.2 and 4.3 was provided by the EMA. The summary findings and the conclusion of the Joint 
Report were prepared and agreed by the two organisations responsible — the EMCDDA and 
Europol. Further details of the seizures and collected samples (including images where available) 
reported to the EMCDDA are provided in Annex 2. The details of deaths associated with 
5-(2-aminopropyl)indole that have been reported to the EMCDDA are provided in Annex 3.
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3.  Information required by Article 5.2 of the 
Decision
The order and titles of subsections 3.1 to 3.8 and section 4 below are as they appear in Article 
5.2(a) to (h) and Article 5.3(a) to (c) of the Decision. Moreover, all sections are cross-referenced 
with those set down in the Decision.
3.1  Chemical and physical description, including the names under 
which the new psychoactive substance is known — Article 
5.2(a) of the Decision
Chemical description and names
5-(2-Aminopropyl)indole is a synthetic derivative of indole substituted at the phenyl side of the 
indole ring system (position 5). It is a positional isomer of alpha-methyltryptamine (AMT) which 
belongs to the tryptamine family, many of which are hallucinogenic. However, 5-(2-aminopropyl)
indole also contains the sub-structure of alpha-methylphenethylamine and therefore could be 
considered to be a substituted phenethylamine, many of which are stimulants. Limited data suggests 
that 5-(2-aminopropyl)indole has stimulant effects.
The structural core of 5-(2-aminopropyl)indole is formed by the indole nucleus. Additional names 
that may be encountered include 1-(1H-Indol-5-yl)propan-2-amine, α-methyl-1H-indole-5-ethanamine 
and 2-(1H-indol-5-yl)-1-methyl-ethylamine. A common abbreviation used for 5-(2-aminopropyl)indole 
is 5-IT. To a lesser extent the abbreviation 5-API is also used. Both these abbreviations are used by 
Internet retailers advertising 5-(2-aminopropyl)indole as well as in discussion on Internet drug 
forums. This suggests that ‘5-IT’ and ‘5-API’ are used as ‘street names’.
Excluding the abstractable proton on the nitrogen atom, a total number of six positional isomers 
exist that can carry the 2-aminopropyl side chain. With the exception of the 3-(2-aminopropyl)
indole isomer (alpha-methyltryptamine: AMT (3)) relatively little has been reported in the published 
literature about the five remaining analogues.
(3)  Other abbreviations and code names for AMT found in the literature include: α- methyltryptamine, AMT, α-MT, 3-IT, 
IT-290, IT-403, U-14, 162-E, Ro 3-0926, NSC 97069, Indopan
95-(2-aminopropyl)indole
Figure 1.  The numbered molecular structure, formula, weight and monoisotopic 

















Identification and analytical profile
Chemical Abstract Service (CAS) Registry Numbers: 3784-30-3 (racemic base); 96875-04-6 
(ethanedioate, 1:1); 1336260-35-5 ((αR)-enantiomer); 1336564-72-7 ((αS)-enantiomer).
Colour screening test (free base): Keller: slightly violet; van Urk: red (Hofmann and Troxler, 1963; 
Troxler et al., 1968).
High performance liquid chromatography diode array detection (λmax/nm): 218.3 and 272.8 
(Elliott et al., 2012).
Melting points: free base 81–83 °C (petroleum ether/benzene); dioxalate salt 199–201 °C 
(methanol/diethyl ether) (Hofmann and Troxler, 1963; Troxler et al., 1968).
Nuclear Magentic Resonance spectroscopy (NMR) data of 5-(2-aminopropyl)indole succinate (4): 1H 
NMR (300 MHz, CD3OD): δ 7.42 (1H, br d, J = 1.1 Hz, H-4), 7.37 (1H, d, J = 8.3 Hz, H-7), 
7.23 (1H, d, J = 3.2 Hz, H-3), 6.98 (1H, dd, J = 8.3 Hz, J =1.7 Hz, H-6), 6.41 (1H, dd, J = 3.2 
Hz, J = 0.8 Hz, H-2), 3.57-3.45 (1H, m (consistent with predicted dqd), α-CH), 3.02 (1H, dd, Jgem 
= 13.8 Hz, 3J = 6.5 Hz, CHAHB), 2.86 (1H, dd, Jgem = 13.8 Hz, 3J = 8.0 Hz, CHAHB), 2.51 (4H, s, 
succinate), 1.26 (3H, d, 3J = 6.6 Hz, CH3). 13C NMR (75 MHz, CD3OD): δ 179.4 (succinate), 
137.0 (C-7a), 129.9 (C-3a), 127.5 (C-5), 126.3 (C-3), 123.5 (C-6), 121.8 (C-4), 112.6 (C-7), 
102.2 (C-2), 50.8 (α-CH), 42.2 (CH2), 32.9 (CH2, succinate), 18.5 (CH3) (Elliott et al., 2012).
Mass spectrometry data: 5-(2-aminopropyl)indole (5-IT) and 3-(2-aminopropyl)indole (AMT) have 
been found to produce virtually identical mass spectra, especially when applying conventional 
Electron Impact-Mass Spectrometry (EI-MS) procedures. Thus, all six potential 2-aminopropyl isomers 
may be expected to yield identical mass spectral data. However, they are easily distinguishable 
from each other by chromatographic techniques if the reference materials are available for 
comparison.
(4)  NMR data is provided for 5-(2-aminopropyl)indole succinate as this is the form that has been encountered in 
collected samples.
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Key fragments observed under EI-MS conditions (m/z): 44 (base peak), 131, 130, 77, 103, 117. 
The M•+ (m/z 174) may be detectable at a minor relative abundance but may also be absent. 
Chemical Ionisation-Mass Spectrometry (CI-MS) (methanol as liquid CI reagent) gave the [M+H]+ at 
m/z 175 as the base peak and a prominent fragment at m/z 175 following the loss of NH3. 
Positive electrospray tandem mass spectra (m/z): 77, 103, 117, 130, 143, 158 (relative 
abundance values dependent on collision energy) with some in-source fragmentation of the 
protonated molecule at m/z 175 (Elliott et al., 2012).
The REACH registered substances database hosted by the European Chemicals Agency (ECHA) 
was searched using the CAS Registry Numbers listed above and no information was found.
Physical description
The free base form of 5-(2-aminopropyl)indole has been described to form skewed prisms. The 
dioxalate salt form has also been documented. It has been reported that some Internet retailers (5) 
have advertised 5-(2-aminopropyl)indole as the succinate salt. NMR data produced as part of the 
analysis of one of the collected samples of 5-(2-aminopropyl)indole (reported by the United Kingdom) 
was found to be consistent with the succinate form (see data above).The Internet search conducted by 
the EMCDDA also noted that 5-(2-aminopropyl)indole hydrochloride was being offered for sale.
Reports from seizures and collected samples have noted the presence of 5-(2-aminopropyl)indole in: 
brown, pale/light brown or beige powders; beige tablets bearing markings resembling the Lexus 
logo (6); brown glittery tablets; blue/green unmarked tablets; blue unmarked tablets commercially 
packaged as ‘BENZO FURY’; capsules; and, in residues on a spoon and in the liquid recovered 
from a syringe.
A more detailed description of 5-(2-aminopropyl)indole seizures and collected samples encountered 
can be found in subsections 3.2.1 and 3.2.2 below.
3.2  Information on the frequency, circumstances and/or quantities 
in which a new psychoactive substance is encountered, and 
information on the means and methods of manufacture of the 
new psychoactive substance — Article 5.2(b) of the Decision
3.2.1 Information provided to Europol
Europol received replies from 22 Member States as well as Norway.
(5)  The term ‘Internet retailers’ is used in this report to describe Internet shops that offer new psychoactive substances 
for sale often advertised as ‘legal highs’ and ‘research chemicals’.
(6)  It is common to find markings on tablets sold as ‘ecstasy’ including those of popular cultural and iconic brands 
often having an association with quality. Lexus is a luxury Japanese car manufacturer.
115-(2-aminopropyl)indole
The level of production, distribution and trafficking
No reports were received that indicated licit or illicit production of 5-(2-aminopropyl)indole.
Portugal reported that the Drugs Department of the Judicial Police stated that 5-(2-aminopropyl)
indole is ‘a precursor used to synthesize drugs’. Europol has requested more information and 
clarification of this statement.
Finland reported that level of distribution of 5-(2-aminopropyl)indole is ‘not so high’. No seizures 
were reported by Finnish authorities. There was, however, an indication that Customs have more 
information on this phenomenon. Europol requested further clarification of the Finnish report.
Germany reported the seizure of 1.35 grams of 5-(2-aminopropyl)indole and further 0.22 grams of 
5-(2-aminopropyl)indole together with traces of MDAI (methylenedioxyaminoindane) on 2 May 
2012 in Hanover from an unconscious person (together with other new psychoactive substances) 
(7). The person subsequently stated that he had bought the substances via the internet from an 
online shop based in the United Kingdom.
A further seizure was reported by Bavarian police. In this case final forensic examination confirmed 
the presence of the 5-(2-aminopropyl)indole as main active agent in the tablet, which had round 
shape, break line, weight 0.15 grams, dimension 0.6 cm and height 0.4 cm.
In addition, checks on the Internet revealed that 5-(2-aminopropyl)indole is known among drug 
users and is offered as ‘legal alternative on the Internet’. The compound is chemically close to 
phenethylamine derivatives such as 5-APB or 4-APB – this matter together with the fact that so far no 
adequate reference material is available in Germany impedes the identification of 
5-(2-aminopropyl)indole.
Germany also indicated that there is no information on the trafficking of 5-(2-aminopropyl)indole in 
Germany. However, the Internet ‘is full with offers’ of 5-(2-aminopropyl)indole and most of the 
online shops ship the offered substances especially to Europe.
Sweden reported seizures amounting to a total of 30.87 grams of powder and 54 tablets. Europol 
has requested further information on these seizures.
Denmark reported one seizure that arrived by mail. So far, Danish authorities are only aware of 
5-(2-aminopropyl)indole distribution on the Internet. They believe that distribution channels are 
outside of Denmark, and end users purchase from the Internet with delivery through the mail 
service.
(7) Reported by the Federal Criminal Police Office (BKA).
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3.2.2  Information provided to the EMCDDA
Seven Member States (Denmark, Germany, Finland, Hungary, the Netherlands Sweden and the 
United Kingdom) and Norway reported detections of 5-(2-aminopropyl)indole (8).
It is noteworthy that several Member States have reported that many forensic and/or toxicological 
laboratories do not currently have validated procedures for the confirmation of 5-(2-aminopropyl)
indole in seized, collected and biological samples. Due to the lack of certified reference material 
(that only became available in August 2012) the laboratories could not distinguish 
5-(2-aminopropyl)indole from the related compound AMT (which has also been detected in samples 
seized on the drug market). Furthermore, in the case of biological samples there is no rapid 
qualitative screening method for the detection of 5-(2-aminopropyl)indole. Overall, this may lead to 
under-reporting of 5-(2-aminopropyl)indole.
Seizures
Seven Member States (Denmark, Germany, Finland, Hungary, the Netherlands Sweden and the 
United Kingdom) and Norway reported seizures of 5-(2-aminopropyl)indole.
5-(2-Aminopropyl)indole has typically been seized in powder form, as well as in tablets and capsules. 
Where information has been provided, quantities of powder ranged from 0.2 grams (Hungary) to 
20.5 kilograms (the Netherlands). Hungary reported a seizure of 7 beige tablets bearing markings 
resembling the Lexus logo (9). This may suggest that 5-(2-aminopropyl)indole is being sold as ’ecstasy’, 
as Europol have reported that tablets containing MDMA and bearing this logo, as well as a tablet 
punch (for imprinting logos on tablets as part of the manufacturing process) have been seized in the 
past. In Sweden, blue/green unmarked tablets and brown glittery tablets were also seized. In the 
United Kingdom, blue unmarked tablets were seized from a head shop and were found in 
commercial packages marked ‘BENZO FURY’ that also displayed an image of the chemical structure 
of 5-APB (5-(2-aminopropyl)benzofuran) (10). There has been one report of residues found on a spoon 
and one report where 5-(2-aminopropyl)indole was recovered from the liquid in a syringe (Hungary). 
This may suggest that 5-(2-aminopropyl)indole is being injected by some users.
Denmark reported one seizure of 5.1 grams of a light brown powder seized on 19 July 2012 by 
customs (Haderslev). The powder was in a small transparent bag labelled as: ‘5g 5-IT, Research 
 (8)  ‘Detections’ is an all encompassing term, which may include seizures and/or collected and/or biological samples. 
Seizure means a substance available (seized) through law enforcement activities (police, customs, border guards, 
etc.). Collected samples are those that are actively collected by drug monitoring systems (such as test purchases) 
for monitoring and research purposes. Biological samples are those from human body fluids (urine, blood, etc.) 
and/or specimens (tissues, hair, etc.).
 (9)  It is common to find markings on tablets sold as ‘ecstasy’ including those of popular cultural and iconic brands 
often having an association with quality. Lexus is a Japanese car manufacturer.
(10)  Whilst 6-APB was originally marketed as ‘Benzo Fury’ (or related synonyms such as ‘BenzoFury’, ‘Benzo-fury’, 
’Benzo’, and ‘Fury’), the isomer 5-APB has also been confirmed in products sold as ‘Benzo Fury’. ‘Benzo Fury’ 
products appear to get their name from the benzofuran chemical ring system which is present at the core of the 
molecule. Other substances have been reported in products sold as ‘Benzo Fury’ (see section 3.4.2).
135-(2-aminopropyl)indole
Chemical, Not for human consumption’. The bag was inside a ‘normal’ brown envelope, and 
without any sender. The post came from the United Kingdom.
Finland reported 11 seizures weighing a total of 26 grams. One of the seizures was 1.1 grams of 
a light brown powder seized on 1 April 2012 by customs (Helsinki) in the incoming mail.
Germany reported one seizure of 1.35 grams and 0.22 grams together with traces of MDAI 
(methylenedioxyaminoindane) seized on 2 May 2012 by police (Hanover). These were seized from 
an unconscious person (together with other new psychoactive substances). The person subsequently 
stated that he had bought the substances via the internet from an online shop based in the United 
Kingdom.
Hungary reported 8 seizures, the first of which was in April 2012. One seizure of 2.4 grams of a 
beige powder in April 2012 was recovered from the scene of a case with two deaths (described in 
section 3.4.1). 97.3 grams of a brown powder was seized in August 2012 by police along with a 
set of digital scales which bore traces of 5-(2-aminopropyl)indole. The Hungarian national focal 
point informed the EMCDDA that the circumstances of the case suggest the distribution of 
5-(2-aminopropyl)indole as well as other new psychoactive substances and controlled drugs using 
the postal system (the business covered the whole of Hungary).
The Netherlands reported one seizure of 20.5 kilograms made by customs. Further details are not 
available at this time.
Sweden reported 27 seizures. 23 of these were reported by the police and comprised 30.87 
grams of powder and 54 tablets. The first seizure was comprised of 13 grams of beige powder 
and was seized on 16 May 2012. In addition, ethylphenidate was also detected in this powder. 
This is a potentially significant finding given the detection of ethylphenidate in three non-fatal 
intoxications in Sweden where 5-(2-aminopropyl)indole was also detected. Customs reported a total 
of 4 seizures comprised of three seizures of a brown powder weighing a total of 11.07 grams and 
one seizure of 5 tablets. The three seizures of powder were sent from Spain. The package 
containing tablets was sent from the United Kingdom.
The United Kingdom reported two seizures. The first seizure was on 9 June 2012 and comprised 
116 branded packets marked ‘BENZO FURY’ that were recovered from a head shop. Each packet 
contained one blue unmarked tablet. This seizure was made during the police investigation into one 
of the deaths reported by the United Kingdom where the presence of 5-(2-aminopropyl)indole was 
confirmed (see section 3.4.1 below). The police were aware that the ‘Benzo Fury’ product 
reportedly consumed by the deceased had been purchased at the head shop.
Other items of interest recovered from the head shop were: Yellow capsules labelled ‘benzofury’ 
found to contain brown powder containing 5-APB (5-(2-aminopropyl)benzofuran) or 6-APB 
(6-(2-aminopropyl)benzofuran). 31 grams of brown powder found to contain 5-APB or 6-APB. 174 
packages (98 of one type and 76 of a second type) each containing 1 gram of crystalline 
substance identified as methylthienylpropamine (MPA).
The second seizure was from the British Crown Dependency of the Bailiwick of Guernsey and made 
by customs on 8 September 2012. The seizure was comprised of seven red and white capsules 
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with no markings. In addition D2PM (diphenylprollinol) was also detected in these capsules. The 
capsules were seized along with a number of controlled drugs (Class B) from a person arriving on 
Guernsey. Further details on this case are not currently available.
Norway reported one seizure of 1 gram in a small bag with zip-lock seized on 17 April 2012 by 
Customs authorities at Oslo airport. In addition, 6-APB (1000 tablets), and a mixture of AM-2201 
and AM-2233 (both synthetic cannabinoids) in green plant material were also seized. The 
consignment originated from the United Kingdom.
Biological samples
Two Member States (Sweden and the United Kingdom) reported a total of 19 deaths where 
5-(2-Aminopropyl)indole was detected (Sweden, 15 deaths; the United Kingdom, 4 deaths). Two deaths 
were reported by Hungary where 5-(2-aminopropyl)indole was detected in powder found at the scene 
of the deaths. Due to the similarities between 5-(2-aminopropyl)indole and AMT under certain analytical 
conditions, the powder was initially thought to contain AMT. AMT was also reported in the post-mortem 
biological samples. The biological samples from these cases are no longer available for re-analysis. 
However, the Hungarian national focal point noted that ‘based on the active agent identified in the 
substance found next to the bodies it is assumed that the cause of the deaths was 5-(2-aminopropyl)
indole intoxication rather than AMT intoxication’ (further details are provided in Annex 3).
Collected samples
One Member State (United Kingdom) reported two collected samples of 5-(2-aminopropyl)indole. In 
April 2012, a sample was purchased from an Internet retailer (buyresearchchemicals.co.uk). The 
product was supplied as a brown powder. In May 2012, a further sample was purchased from an 
Internet retailer (Polatzo head shop). The product was supplied as a pale brown powder and cost 
GBP22.50 for 500 milligrams (11). Further details of these collected samples, including information 
on the product labels, are provided in Annex 2.
3.3  Information on the involvement of organised crime in the 
manufacture or trafficking of the new psychoactive substance 
— Article 5.2(c) of the Decision
Germany reported that ‘no direct hints on any kind of organised crime were indentified. However 
bearing in mind the easy availability of 5-(2-aminopropyl)indole same as a plenty of other new 
psychoactive substances via internet-shops (e.g. www.benzo-fury.me.uk, www.highstore.net, www.
buckledbonzi.co.uk), also in large amounts in and outside of the EU indicate at least a certain 
degree of organisation.’
Denmark reported that, ‘so far we do not believe the distribution of 5-IT in Denmark is organized’.
(11) The actual weight supplied was not reported.
155-(2-aminopropyl)indole
Money laundering aspects
No information was received on money laundering related to the production and/or trafficking of 
5-(2-aminopropyl)indole.
Violence in connection with production, wholesale and distribution
No information was received on incidents of violence in connection with the production, wholesale 
and/or trafficking of 5-(2-aminopropyl)indole.
3.4  A first indication of the risks associated with the new 
psychoactive substance, including the health and social risks, 
and of the characteristics of users — Article 5.2(d) of the 
Decision 
3.4.1 First indication of health risks
Non-fatal intoxications associated with 5-(2-aminopropyl)indole
Two Member States (Sweden and the United Kingdom) reported a total of 15 non-fatal intoxications 
associated with 5-(2-aminopropyl)indole (12).
Sweden reported 13 cases from the Swedish Poisons Information Centre between January and 
September 2012 where 5-(2-aminopropyl)indole was detected.
Of the 13 cases, 11 were male and 2 were female. Their ages ranged between 17 and 52, however 
the most common age was 20 to 30 years with 8 of the 13 falling into this bracket. In five cases, the 
individual stated they had taken ‘5-IT’ (a commonly used abbreviation for 5-(2-aminopropyl)indole), in 
four cases the stated intake was ‘benzofury’, whilst three mentioned taking ethylphenidate (one in 
combination with ‘benzofury’, one with 5-(2-aminopropyl)indole and one on its own). One person 
stated they had taken MDPV (methylenedixoypyrovalerone), one said they had been ‘drinking only 
coca cola from an unknown source’ and the remaining person stated they had taken ‘an unknown 
substance’. 5-(2-Aminopropyl)indole was analytically confirmed in each case although the 
concentration was not determined. Other drugs detected in these cases were: ethylphenidate, 4-,5- or 
6-APB, 4-methylethcathinone, buprenorphine, methylphenidate, methylphenidate metabolites, 
4-fluoroamphetamine, oxazepam, temazepam, diazepam metabolites, methylthienylpropamine, 
methoxetamine, 4-hydroxymidazolam (midazolam metabolite), ketamine, GHB (gamma-
hydroxybutyrate), PMMA (para-methoxymethamphetamine), amphetamine, N-methamphetamine, 
benzoylecgonine (cocaine metabolite), ethanol and metabolites.
(12)  The German police reported to Europol that the powder seized in Hanover was seized from an unconscious 
person. It is not known if this is a non-fatal intoxication associated with 5-(2-aminopropyl)indole as further details 
are not available.
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The route of administration of 5-(2-aminopropyl)indole was indicated in one case where the person 
reported having taken it by nasal insufflation. Three of the 13 individuals reported that they sourced 
5-(2-aminopropyl)indole from the Internet (the remaining ten individuals did not report the source of 
supply).
The reported symptoms included dilated pupils, sweating, restless, disorientated, agitated, anxiety, 
high heart rate, high blood pressure and high body temperature.
One example of a non-fatal intoxication that was provided was of an eighteen year old female who 
had taken 1 capsule of 5-(2-aminopropyl)indole of unknown strength. Fifteen hours after 
administration, the subject was restless, agitated, disorientated, shivering, sweating, with dilated 
pupils and a heart rate of 160/min. Body temperature rose to 38.6 ºC. ‘The patient was treated 
with sedating drugs without sufficient effect. She was sedated and put on respirator. The following 
day she was full of anxiety but otherwise in a stable condition.’
The United Kingdom reported that there were two non-fatal intoxications associated with the second 
death detailed below. The two individuals had also reportedly ingested some ‘Benzo Fury’ from the 
same source as the deceased. They were also seen at the hospital but neither appeared to have 
suffered any significant toxic effects. No further information on drug history or the amounts of 
‘Benzo Fury’ taken was available.
Deaths associated with 5-(2-aminopropyl)indole
Three Member States (Sweden, the United Kingdom and Hungary) reported a total of 21 deaths 
associated with 5-(2-aminopropyl)indole (13).
Sweden
Sweden reported that the National Laboratory of Forensic Toxicology (RMV) have observed 
5-(2-aminopropyl)indole in 15 post-mortem examinations. These were performed between April 
2012 and 30 June 2012. In 14 of the cases the cause of death was considered to be related to 
5-(2-aminopropyl)indole. In the remaining case the cause was ‘disease’. In 14 cases the 
5-(2-aminopropyl)indole concentration in post-mortem blood ranged from 0.7 to 5.2 µg/g blood. In 
one case the concentration of 5-(2-aminopropyl)indole was 18.6 µg/g femoral blood. All of the 
deceased were male. 13 were aged between 20 and 30 years, the remaining two were over 30 
years old. In two cases 5-(2-aminopropyl)indole was the only substance detected. In the remaining 
cases, 5-(2-aminopropyl)indole was found in combination with ‘pharmaceuticals’ or ‘other drugs’ 
(not specified).
(13)  In the two deaths reported by Hungary, AMT was reported as being detected in post-mortem biological samples. 
However, it is assumed that the cause of the deaths was 5-(2-aminopropyl)indole intoxication rather than AMT 
intoxication. See section 3.2.2, ‘Biological samples’.
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United Kingdom
The United Kingdom reported four deaths. Details are only provided for two of these cases, both of 
which occurred in June 2012. The deceased were both male; one was 33 years old, the other was 
19 years old.
The cause of death in the first case (33 year old) was ‘fatality following the ingestion of ‘Benzo 
Fury’’ and certified as ‘5-(2- aminopropyl)indole (5-API; 5-IT) and Benzofuran toxicity’. The male 
was treated in hospital prior to death. Analysis of the blood revealed an approximate 
5-(2-aminopropyl)indole concentration of 0.379 mg/L in unpreserved post-mortem blood. Other 
drugs detected in the blood included 5-APB (0.016 mg/L), 6-APB (0.057 mg/L), diazepam (0.037 
mg/L), nordiazepam (0.009 mg/L), temazepam (0.001 mg/L) and AMT (less than 0.01 mg/L). 
Urine analysis detected amphetamine, 5-(2-aminopropyl)indole, 5-APB, 6-APB, AMT and 
benzodiazepines. In addition, 5-(2-aminopropyl)indole, 5-APB, 6-APB, AMT and diazepam were 
detected in the stomach contents.
In the second case (19 year old), the toxicological investigation revealed 5-(2- aminopropyl)indole 
at a concentration of approximately 0.513 mg/L in ante-mortem blood (the deceased was admitted 
to hospital prior to death) and approximately 0.30 mg/L in unpreserved post-mortem blood. Other 
drugs detected included MDMA (0.468 mg/L ante-mortem blood, 0.502 mg/L post-mortem blood), 
MDA (0.036 mg/L ante-mortem blood, 0.046 mg/L post-mortem blood), 6-APB (0.005 mg/L 
post-mortem blood only), atropine and lignocaine. These drugs were also detected in the urine and 
stomach contents. It was noted that there was a high concentration of MDMA, which in isolation 
was considered to be at a fatal level. However, a cumulative/synergistic effect of 5-(2-aminopropyl)
indole was not excluded and the cause of death was recorded as ‘multidrug toxicity’. This case is 
linked to the seizure of 116 blue tablets in branded packets labeled as ‘BENZO FURY’ containing 
5-(2-aminopropyl)indole (detailed in section 3.2.2 above).
The remaining two deaths from the United Kingdom were reported in a letter to the British Medical 
Journal. The letter reports that 5-(2-aminopropyl)indole was detected in the post-mortem blood 
samples of two young adults. The authors note that 5-(2-aminopropyl)indole was ‘found in 
combination with other drugs in one case. In the other, 5-APB/6-APB’ (Seetohul et al., 2012). It 
was ascertained from the national focal point that these cases were distinct from the other two 
cases reported by the United Kingdom. However, no further details are available at this time.
Hungary
As noted, the two deaths reported by Hungary were originally thought to be related to AMT which 
was detected in post-mortem biological samples. The deceased, a 40-year-old male and a 35-year-
old female were found together in a flat. The pathological cause of death in each case was 
‘circulatory failure and respiratory failure, where the direct causes of death… were the results of 
5-IT intoxication’ and in the case of the female ‘the respiration of vomited content of stomach might 
had a limited impact too’. There were signs of ‘prolonged sexual intercourse, extreme hyperthermia 
and the use of new psychoactive substances’.
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The post-mortem concentrations (determined as AMT) were 34 mg/L and 84 mg/L respectively. 
These figures are provided only to show them relative to each other. The biological samples were 
no longer available for re-analysis. However, the re-analysis of powders found at the scene 
identified the presence of 5-(2-aminopropyl)indole and not AMT. The Hungarian national focal 
point noted that ‘based on the active agent identified in the substance found next to the bodies it is 
assumed that the cause of the deaths was 5-(2-aminopropyl)indole intoxication rather than AMT 
intoxication.’
Information on toxicity, tolerance and dependence potential
The structured literature search undertaken for the preparation of this report did not find any 
published information specifically related to toxicity, tolerance nor the dependence producing 
potential of 5-(2-aminopropyl)indole.
While detailed pharmacological investigations on 5-(2-aminopropyl)indole do not appear to have 
been published (14), one study that investigated the ability of 5-(2-aminopropyl)indole and its five 
isomers to inhibit monoamine oxidase (MAO) was identified. The assay method was based on the 
ability of guinea pig liver homogenate to absorb oxygen generated from serotonin as the substrate. 
The activity was expressed as percentage inhibition. The IC50 values for 5-(2-aminopropyl)indole, 
6-(2-aminopropyl)indole (6-IT) and 3-(2-aminopropyl)indole (AMT), for example, were 2.2 × 10-5, 
4.6 × 10-6 and 5.8 × 10-5 M, respectively. These data indicate that 6-IT was the most potent 
inhibitor amongst those three substances. These substances were also evaluated for their ability to 
antagonise pentylenetetrazole/reserpine-induced tonic extensor seizures in mice. 5-(2-Aminopropyl)
indole appeared to be less active than 6-IT but more active than AMT with regards to anti-reserpine 
activity (Cerletti et al., 1968). Overall, the significance of these findings in relation to humans is 
unclear.
Shulgin and Shulgin (1997) provide some limited data noting that 5-(2-aminopropyl)indole may 
show long-lasting stimulant properties in humans (for about twelve hours) when 20 mg was given 
orally. Effects reported were increased heart-rate, anorexia, diuresis, and slight hyperthermia. No 
information is provided on the methodology of the experiment or the number of volunteers.
In some of the non-fatal intoxications and deaths associated with 5-(2-aminopropyl)indole that were 
reported, symptoms typical of monoaminergic toxicity have been noted. These include hyperthermia 
along with dilated pupils, sweating, increased heart rate, high blood pressure, agitation, 
restlessness, disorientation and anxiety.
Information from Internet drug user discussion forums suggest that the self-reported routes of 
administration for 5-(2-aminopropyl)indole include oral (such as ‘bombing’ (15)) and insufflation. 
Reported doses used include: ‘20mg’ [route of administration not specified], ‘80 mg orally’, 
(14)  A literature search on 5-(2-aminopropyl)indole revealed a translated article (USSR, Academy of Sciences) on 
serotonergic properties of several tryptamines. An inspection of the English translation did not appear to yield 
conclusive data on 5-(2-aminopropyl)indole (Buznikov et al., 1965).
(15) ‘Bombing’ is where a drug is wrapped in cigarette paper (or similar) prior to swallowing.
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‘bombed 100 mg’, ‘150Mg swallowed’, ‘insufflated 65 mg’. There is also one brief user report of 
what appears to be the intravenous injection of 5-(2-aminopropyl)indole (16).
Information from the EU pharmacovigilance system
According to information received from the EMA, there are no reports associated with 
5-(2-aminopropyl)indole in the EudraVigilance system.
3.4.2 Characteristics of users
Prevalence data on the use of 5-(2-aminopropyl)indole are not available. Information included in this 
report (including seizures, collected samples, non-fatal intoxications and deaths) provides some 
information about the characteristics of users and how 5-(2-aminopropyl)indole appears on the market.
Some Internet retailers offer 5-(2-aminopropyl)indole as a drug in its own right. This has been 
confirmed by collected samples and is supported by discussions on Internet drug user forums. 
Additionally, the United Kingdom reported that seized samples of branded products labelled as 
‘BENZO FURY’ from a bricks and mortar head shop contained 5-(2-aminopropyl)indole. Information 
from non-fatal intoxications and deaths reported by Sweden and the United Kingdom suggests that 
some individuals may have been exposed to 5-(2-aminopropyl)indole as a result of using products 
labelled as ‘Benzo Fury’ or ‘6-APB’. However, the prevalence of 5-(2-aminopropyl)indole in such 
products relative to other substances is not known.
Hungary reported the seizure of seven tablets that contained both 5-(2-aminopropyl)indole and 
methylthienylpropamine bearing markings resembling the Lexus logo (see Annex 2). As noted, 
Europol have reported MDMA tablets and a tablet punch (for stamping logos on tablets) bearing 
the Lexus logo have been seized in the past. It may be the case that some ecstasy users are at risk 
of exposure to 5-(2-aminopropyl)indole. However, as noted, the total number of such types of 
tablets containing 5-(2-aminopropyl)indole that have been reported so far is small and limited to 
one country.
Hungary reported that 5-(2-aminopropyl)indole has been found in residues on a spoon and in the 
liquid recovered from a syringe. The assessment of the Hungarian national focal point is that 
5-(2-aminopropyl)indole is being injected.
Information suggests that 5-(2-aminopropyl)indole is taken orally, insufflated, and may be injected.
Data from the 2011 Mixmag survey (a non-probablistic convenience sample Internet survey 
commissioned by the UK dance music magazine Mixmag, n=2560) found that self-reported lifetime 
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and last year prevalence of use of ‘Benzofury’ in this group was 2.7 % and 2.3 % respectively. In 
comparison self-reported lifetime and last year prevalence of MDPV (methylenedioxypyrovalerone) 
was 4.4 % and 3.0 % respectively; MDAI (5,6-methylenedioxy-2-aminoindane) was 6.7 % and 4.7 
% respectively; BZP (1-benzylpiperazine) was 17.2 % and 5.0 % respectively; and, mephedrone 
(4-methylmethcathinone) was 61.0 % and 51.0 % respectively.
Kelleher et al., (2011), also using a non-probablistic convenience sample Internet survey of self-
reported new psychoactive substance users, the majority of which were from Ireland (n=329), 
found that of the 159 respondents who reported using ‘party pills’ and ‘liquid highs’, 1.3 % (i.e. 2 
respondents out of 159) had used a product named ‘Benzo Fury’; while none of the respondents 
reported use of ‘6-APB’.
Both these surveys predate the detection of 5-(2-aminopropyl)indole. While they provide some 
indication of the use of ‘Benzofury’ products the results are not generalisable to other groups and 
populations.
Information on the composition of ‘Benzo Fury’ products
Although Internet retailers typically advertise ‘Benzo Fury’ products as containing 6-APB or 5-APB, a 
structured search of the information available on the European database on new drugs (EDND) (17) 
found that seized and collected samples of ‘Benzo Fury’ products have contained: 6-APB; 5-APB; 
D2PM; pentylone with caffeine, lidocaine and procaine; AM-2201 (tentative identification); and, 
5-(2-aminopropyl)indole.
Additionally, published studies involving the analysis of collected and biological samples suggest 
that ‘Benzo Fury’ products contain: 6-APB; 5-APB; D2PM; and, 1-benzylpiperazine (BZP) with 
3-trifluoromethylphenylpiperazine (3-TFMPP) and caffeine (Ayres and Bond, 2012; Baron et al., 
2011; Wood et al., 2011; Wood et al., 2012).
3.5  Information on whether or not the new substance is currently 
under assessment, or has been under assessment, by the UN 
system — Article 5.2(e) of the Decision
The World Health Organization is the specialised United Nations agency designated for the 
evaluation of the medical, scientific and public health aspects of psychoactive substances under the 
Single Convention on Narcotic Drugs, 1961 and the Convention on Psychotropic Substances, 
1971 (hereafter, ‘United Nations drug conventions’). On 10 October 2012, the World Health 
Organization informed the EMCDDA that 5-(2-aminopropyl)indole is currently not under assessment 
and has not been under assessment by the United Nations system and no such assessment is 
planned.
(17) Including Reporting Forms, Progress and Annual Reports, and Project Match.
215-(2-aminopropyl)indole
3.6  The date of notification on the Reporting Form of the new 
psychoactive substance to the EMCDDA or to Europol — 
Article 5.2(f) of the Decision
The first official EMCDDA–Europol notification of 5-(2-aminopropyl)indole dates from 1 June 2012 
from the Norwegian national focal point. The reporting form details a seizure of one zip-lock bag 
containing one gram of light brown powder intercepted at Oslo Airport, Gardermoen, on 17 April 
2012 by the customs authorities. The identification was based on the analytical technique of 
GC-MS alone.
5-(2-Aminopropyl)indole was added to the list of new psychoactive substances monitored by the 
EMCDDA and Europol via the European Union early warning system and a profile of the substance 
was created in the EMCDDA European database on new drugs (EDND). Analytical details and 
background information have been exchanged on various occasions between EMCDDA, Europol 
and the Member States. The Commission and the EMA were kept duly informed.
3.7  Information on whether or not the new psychoactive substance 
is already subject to control measures at national level in a 
Member State — Article 5.2(g) of the Decision
One Member State, Denmark, controls 5-(2-aminopropyl)indole under drug control legislation 
derived from their obligations under the United Nations drug conventions. On the recommendation 
of the Danish Health and Medicines Authority, the Danish Minister for Health decided to add 
5-(2-aminopropyl)indole (1-(1H-indol-5-yl)propan-2-amin) to the Danish lists of controlled substances, 
List B. On 28 September 2012, the Minister signed an Executive Order amending the Executive 
Order on Euphoriant Substances. This entered into force on 30 September 2012. Subsequently, 
5-(2-aminopropyl)indole may only be used for medical or scientific purposes.
Austria, Hungary and Sweden control 5-(2-aminopropyl)indole using other legislative measures. In 
Austria, 5-(2-aminopropyl)indole is subject to control measures according to the law on new 
psychoactive substances (NPSG). In Hungary, 5-(2-aminopropyl)indole is controlled as a ‘new 
psychoactive substance’ (Government Decree 66/2012) as it is a derivative of 2-phenethylamine 
(therefore meeting the generic definition of phenethylamine derivatives). In Sweden, with effect from 
18 of September 2012, 5-(2-aminopropyl)indole was regulated as a substance hazardous to health 
under the Act on the Prohibition of certain Goods Dangerous to Health (SFS 1999:42).
In Germany, in accordance with diverse articles of the Medical Products Act (Arzneimittelgesetz, 
AMG), trafficking of 5-(2-aminopropyl)indole and keeping 5-(2-aminopropyl)indole for sale are 
forbidden and may be punished (18).
(18)  Spain also noted that ‘these types of substances have to be evaluated and authorized by the Spanish Agency of 
Medicines and Sanitary Products when they are used by humans. This is established by the article 9 of the Law 
29/2006, 26th July, regarding guarantees and rational use of medicines and sanitary products.’
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The remaining 22 Member States, Croatia, Turkey and Norway have reported that 
5-(2-aminopropyl)indole is not under control in their jurisdictions (19).
3.8 Further information — Article 5.2(h) of the Decision
3.8.1  The chemical precursors that are known to have been used for the 
manufacture of the substance
There is no information regarding manufacturing sites, the chemical precursors or the synthetic 
routes used for the 5-(2-aminopropyl)indole that has been detected on the drug market.
One classic approach for the synthesis of 5-(2-aminopropyl)indole includes a condensation reaction 
using indole-5-carboxaldehyde (20) and nitroethane (CH3CH2NO2). The resulting 5-(2-methyl-2-
nitrovinyl)indole can then be reduced with lithium aluminum hydride (LiAlH4) (Hofmann and Troxler, 
1963; Troxler et al., 1968) but other methods and reagents of reduction may equally be 
employable. This is a similar process to the reductive amination used commonly in the manufacture 
of amphetamines. The reactions are feasible in an amateur laboratory setting and do not require 
sophisticated equipment. A further possible route of synthesis that may be applicable to 
5-(2-aminopropyl)indole is the ‘gramine-nitroalkane’ route which can be used to manufacture AMT 
(Brandt et al., 2004). In this particular case, the starting material would then be 1-(1H-indol-5-yl)-
N,N-dimethylmethanamine which, upon reaction with nitroethane, would give the 5-(2-nitropropyl)-
1H-indole intermediate. Reduction of the nitro group would then result in the primary amine 
product, 5-(2-aminopropyl)indole. This particular reaction is not in the published literature. 
Depending on reaction conditions it may yield dialkylated and other by-products (Brandt et al., 
2004). A sub-structure search revealed that 5-(2-aminopropyl)indole exists as a sub-structure of a 
larger molecule. This means that 5-(2-aminopropyl)indole could serve as a starting material for 
further modifications. An example was found in the patent literature in the form of 4-((1-(1H-indol-5-
yl)propan-2-yl)(propyl)amino)-1-cyclohexylbutan-1-one (Reaxys registry number 15343158) (Duphar 
International Research, 1988).
(19)  Italy also provided further information that in “… September (2012), the Italian Ministry of Health in 
collaboration with the Department for Antidrug Policies of the Presidency of the Council of Ministers and with 
the support of the Italian Early Warning System, activated the procedure to include the new psychoactive 
substance 5-(2-aminopropyl)indole, into the list of controlled substances (Table I, President of the Republic 
Decree 309/90). In a few months, the molecule will have the chance to be put under control.” Latvia provided 
information that although 5-IT is not under control at national level, there is a plan to introduce a new generic 
system. If this system is introduced, “all new psychoactive substances including 5-IT will be under control”. 
Finland provided information that they intend to control 5-IT under existing medicines legislation “….the 
decision, however, is not in force yet.” Bulgaria indicated to Europol that the Customs Agency prepared a 
proposal to the National Council of Drugs Substances to put under control some new psychoactive substances, 
including 5-(2-aminopropyl)indole. 
(20)  Indole-5-carboxaldehyde is not under international control and is known to be commercially available. For 
example Italy reported that it is sold by Sigma for EUR155 for 5 grams (http://www.sigmaaldrich.com/catalog/
product/ALDRICH/513830?lang=it&region=IT).
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As noted, information provided by the Portuguese Europol National Unit suggested that 
5-(2-aminopropyl)indole is ‘a precursor used to synthesise drugs’. Europol has requested further 
information on this issue from the Portuguese Europol National Unit.
3.8.2  The mode and scope of the established or expected use of the new 
substance
As noted, 5-(2-aminopropyl)indole has been encountered as powders as well as tablets and 
capsules. These physical forms suggest that common routes of administration may be orally and by 
insufflation. Limited information from reports of non-fatal intoxications, deaths and Internet drug user 
discussion forums appear to support this. The succinate salt of 5-(2-aminopropyl)indole (confirmed 
in the two collected samples reported by the United Kingdom) may be suitable for injection. 
Significantly, Hungary has reported that 5-(2-aminopropyl)indole has been found in residues on a 
spoon and in the liquid recovered from a syringe. The assessment of the Hungarian national focal 
point is that 5-(2-aminopropyl)indole is being injected. One brief user report of what appears to be 
the intravenous injection of 5-(2-aminopropyl)indole has been reported on an Internet drug user 
forum (21). The United Kingdom noted that Internet drug user forums suggest that 5-(2-aminopropyl)
indole is used at home and in nightclubs.
Several countries have noted that 5-(2-aminopropyl)indole is offered for retail sale as a ‘research 
chemical’ on the Internet. Germany reported that 5-(2-aminopropyl)indole is offered for sale 
alongside other new psychoactive substances (www.benzo-fury.me.uk, www.highstore.net and 
www.buckledbonzi.co.uk). Italy also reported a similar observation and noted that 
5-(2-aminopropyl)indole could be bought for GBP22.50 for 500 milligrams (http://www.
officialbenzofury.com/products /5%252dIT.html) and GBP9.50 for 100 milligrams (http://
vip-legals.com/buy-5it-powder; http://www.lookchem.com/5-2-Aminopropyl-indole/). The United 
Kingdom noted that 5-(2-aminopropyl)indole was sold as a ‘unique product’, structurally ‘similar to 
AMT’ with ‘euphoric effects similar to 5-APB’. They reported that 5-(2-aminopropyl)indole could be 
purchased in the form of capsules containing 100 milligrams (e.g. http://www.wide-mouth-frogs.
com/5-it-caps.html) GBP26.00 for 10 capsules or GBP100.00 for 50 capsules. Powders also 
appeared to be offered for sale at GBP10.20 for 250 milligrams (discounted from GBP12.00; 
http://www.benzofury.me.uk/index/155) or in bulk powder GBP6000.00 for 1 kilogram (e.g. 
http://www.plantfoodpalace.com/5-it/page/2/). It was offered for sale in combination with AMT 
by one retailer at a cost of GBP38.00 for 500 milligrams.
In addition to the information given above, the United Kingdom commented that at the time of 
reporting, 5-(2-aminopropyl)indole is ‘not included or has been removed from the stocklist of a 
number of the more well-known retailers’. They further comment that ‘it is unknown whether this is 
related to lack of availability from wholesalers or importers or due to adverse media attention 
concerning the drug (e.g. http://local.stv.tv/glasgow/194611-legal-high-5-it-tablets-recovered-by-
police-are-potentially-fatal/)’.
(21) http://www.drugs-forum.com/forum/showthread.php?t=140331
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The Internet search conducted by the EMCDDA found that as of 6 December 2012, ‘5-IT’ is offered 
for sale by a number of Internet retailers.
3.8.3  Other use of the new psychoactive substance and the extent of such 
use, the risks associated with this use of the new psychoactive 
substance, including the health and social risks
No information was provided by any Member State that indicated that 5-(2-aminopropyl)indole had 
any other use apart from legitimate scientific research and as an analytical reference standard.
From the available information it does not appear that 5-(2-aminopropyl)indole is used in the 
manufacture of a medicinal product in the European Union. However, the collection of information 
cannot be considered exhaustive in the absence of an European Union database on the synthetic 
routes of all medicinal products (22).
(22)  i.e. products that have been granted a marketing authorisation, or where an application for a marketing 
authorisation has been made, or where the marketing authorisation has been suspended.
255-(2-aminopropyl)indole
4.  Information from the EMA as requested 
by Article 5.3 of the Decision
4.1 Marketing authorisation
The 17 Member States, Iceland and Norway which responded to the EMA’s information request 
(see section 2) reported that the new psychoactive substance 5-(2-aminopropyl)indole has not 
obtained a marketing authorisation (23).
4.2 Application for a marketing authorisation
The 17 Member States, Iceland and Norway which responded to the EMA’s information request 
(see section 2) reported that the new psychoactive substance 5-(2-aminopropyl)indole is not the 
subject of an application for a marketing authorisation.
4.3 Suspended marketing authorisation
The 17 Member States, Iceland and Norway which responded to the EMA’s information request 
(see section 2) reported that there had been no cases of a suspended marketing authorisation that 
had been granted in respect of the new psychoactive substance 5-(2-aminopropyl)indole.
(23)  Belgium, Denmark, Estonia, Ireland, Spain, Sweden and Norway provided responses in relation to both human 
and veterinary medicinal products. Germany, Hungary, Italy, Malta, Portugal, Romania, Slovenia, Slovakia and 
the United Kingdom provided responses in relation to human medicinal products. Latvia and Poland provided 
responses in relation to veterinary medicinal products.
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5. Summary of findings
5.1.   5-(2-Aminopropyl)indole is a synthetic derivative of indole substituted at the phenyl side of 
the indole ring system (position 5). It is a positional isomer of alpha-methyltryptamine (AMT) 
which belongs to the chemical family of tryptamines, many of which are hallucinogenic. 
However, 5-(2-aminopropyl)indole also contains the sub-structure of alpha-
methylphenethylamine and therefore could be considered to be a substituted 
phenethylamine, many of which are stimulants. Limited data suggests that 5-(2-aminopropyl)
indole has stimulant effects.
5.2.   The first seizure of 5-(2-aminopropyl)indole was in Norway on 17 April 2012. It was notified 
to the EMCDDA through the EU early warning system on 1 June 2012.
5.3.   Several Member States reported that forensic and/or toxicological laboratories do not 
currently have validated procedures for the confirmation of 5-(2-aminopropyl)indole. This 
was due to the initial lack of certified reference material. This may have led to under-
reporting of 5-(2-aminopropyl)indole detections.
5.4.   Seven Member States and Norway have reported seizures of 5-(2-aminopropyl)indole. These 
were mostly as powders (ranging from 0.2 grams to 20.5 kilograms), tablets and capsules. 
It has also been detected in tablets resembling ‘ecstasy’.
5.5.   The information available suggests that common routes of administration of 
5-(2-aminopropyl)indole may be orally and by insufflation. One Member State reported that 
injection may also occur.
5.6.   There is no information regarding manufacturing sites, the chemical precursors or the 
synthetic routes used for the 5-(2-aminopropyl)indole that has been detected on the drug 
market. One possible route of synthesis is a similar process to the reductive amination used 
commonly in the manufacture of amphetamines. The reactions are feasible in an amateur 
laboratory setting and do not require sophisticated equipment.
5.7.   According to reports provided to Europol there is no information available to suggest the 
involvement of organised crime, or criminal groups, in the production, distribution and 
trafficking of 5-(2-aminopropyl)indole. The substance has been seized at the border of four 
Member States and Norway. In one case this involved a seizure of 20.5 kilograms.
5.8.   One Member State controls 5-(2-aminopropyl)indole under drug control legislation. Two 
Member States control 5-(2-aminopropyl)indole under legislation relating to new 
psychoactive substances. One Member State controls 5-(2-aminopropyl)indole under other 
legislation. One Member State controls 5-(2-aminopropyl)indole under medicine legislation.
5.9.   5-(2-Aminopropyl)indole is currently not under assessment and has not been under 
assessment by the United Nations system.
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5.10.  There are no prevalence data on the use of 5-(2-aminopropyl)indole. In some cases 
5-(2-aminopropyl)indole has been found in ‘Benzo Fury’ products. A non-representative 
Internet survey of readers of a dance music magazine found that 2.3 % of respondents 
reported use of ‘Benzo Fury’ in the last year.
5.11.  Some Member States reported easy access and availability of 5-(2-aminopropyl)indole 
through Internet retailers. It is sold as a drug in its own right and in branded products sold as 
‘Benzo Fury’. In the latter case there is also evidence of supply from bricks and mortar head 
shops.
5.12.  There have been 15 non-fatal intoxications and 21 deaths associated with 5-(2-aminopropyl)
indole in three Member States. These have been reported to the EMCDDA from the 6 July 
2012 to the time of writing the report. The analysis of biological samples shows that 
5-(2-aminopropyl)indole may be used in conjunction with controlled drugs and new 
psychoactive substances.
5.13.  There appear to be no published studies on the toxicity, tolerance and dependence 
producing potential of 5-(2-aminopropyl)indole. Detailed studies on pharmacology also do 
not appear to have been published. One available study suggests that 5-(2-aminopropyl)
indole inhibits monoamine oxidase. The significance of this finding in relation to humans is 
unclear. In some of the non-fatal intoxications and deaths associated with 5-(2-aminopropyl)
indole symptoms typical of monoaminergic toxicity have been noted.
5.14.  5-(2-Aminopropyl)indole has no known human or veterinary medical use in the European 
Union. There is no marketing authorisation (existing, ongoing or suspended) for 
5-(2-aminopropyl)indole in the European Union or in the Member States which responded to 
the EMA.
5.15.  There are no indications that 5-(2-aminopropyl)indole is used for other purposes other than 
as an analytical reference material and in scientific research. At the time of writing the 
report, there is no information that 5-(2-aminopropyl)indole is used in the manufacture of a 
medicinal product in the European Union. However, the collection of information cannot be 
considered exhaustive in the absence of an European Union database on the synthetic routes 
of all medicinal products.
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6. Conclusions
The health and social risks caused by the manufacture, trafficking and use of 5-(2-aminopropyl)
indole, as well as the involvement of organised crime and possible consequences of control 
measures, could be thoroughly assessed through a risk assessment procedure as foreseen by Article 
6 of Council Decision 2005/387/JHA.
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Annexes
Annex 1 — Main information sources
General
1.  EMCDDA and it network of Reitox national focal points — standard reporting and replies to 
Joint Report questionnaire.
2.  Europol and its network of Europol National Units — standard reporting and replies to Joint 
Report questionnaire.
3.  EMA and its network of Member States’ national competent authorities responsible for human 
and veterinary medicinal products — replies to Joint Report questionnaire.
4.  Scientific articles published in peer reviewed journals.
5. Grey literature.
6. Internet sites and drug user discussion forums (including media articles).
7. Personal communications with experts.
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Annex 2 —  Details of seizures and collected samples of 5-(2-aminopropyl)indole (5-IT) 














19/07/2012 One seizure of 5.1 g light 
brown powder 
Customs Haderslev Powder was found in a small transparent bag and with a sticker: ‘5g 
5-IT, Research Chemical, Not for human consumption’. The bag was 
inside a ‘normal’ brown envelope, and without any sender. The post 
came from United Kingdom. Identification based on GC-MS, UPLC-TOF, 
H-NMR.
Finland
01/04/2012 One seizure of 1.1 g of a 
light brown powder
Customs Helsinki Seized in incoming mail. Identification based on NMR.
Germany
02/05/2012 1.35 g and a further 0.22 
g together with traces 
of MDAI (together with 
other new psychoactive 
substances)
Police Hannover The accused stated that he has bought the substances via the internet 
from an online shop in the United Kingdom.
Hungary*
04/2012 2.4 g of a beige powder Police Tapolca Confirmed as 5-(2-aminopropyl)indole
04/2012 Residues on paper, liquid 
in syringe (0.75 ml)
Police Debrecen Confirmed as 5-(2-aminopropyl)indole
04/2012 2.2 g of a brown powder Police Szombathely Confirmed as 5-(2-aminopropyl)indole
05/2012 Residues on spoon Police Szentes Confirmed as 5-(2-aminopropyl)indole
05/2012 10.2 g of a brown 
powder
Police Tata Confirmed as 5-(2-aminopropyl)indole













06/2012 0.2 g of a light-brown 
powder
Police Szigetvár Confirmed as 5-(2-aminopropyl)indole
06/2012 7 beige tablets with ‘Lexus’ 
logo, also containing, 
methylthienylpropamine 
and caffeine
Police Kiskőrös Confirmed as 5-(2-aminopropyl)indole. Weight of tablets: 0.285 g, 
diameter: 8.10 mm, thickness: 5.8 mm. The identification was carried 
out by TLC and GC/MS based on the laboratory’s ‘own’ reference 
materials (their structure was confirmed by NMR).
08/2012 97.3 g of a brown 
powder, residues on 
digital scale
Police Szigetvár In this case the investigation confirmed the fact of dealing both new 
psychoactive substances (according to schedule “C” Gov. Decree 
66/2012) and illicit drugs (covered by the illicit drugs definition of the 
Penal Code). Mail delivery and selling from the flat was also confirmed. 
The business covered the whole country did not concentrate on the area 
of Szigetvár.
Netherlands
Not available 20.5 kg Customs Not available
Sweden
23 seizures incorporating 
30.87 g powder and 54 
tablets.
Police The first seizure comprising 13 g beige powder was seized by the 
police 16/05/2012 in Örnsköldsvik city with identification based on 
GC-MS, GC-IRD and NMR.
Examples of seized tablets: One type of tablet in 6 materials: These 
are blue, green melange; round and curved with border; diameter 9.0 
mm, width 4.0 mm, weight 0.25 g. Another type of tablet that occurred 
only in one material: brown, glittery tablet; round and flat and scored; 














Four seizures in total, 
comprising: three seizures 
of a brown powder weight 
a total of 11.07 g. One 
seizure of 5 tablets
Customs Arlanda Airport, 
Sweden.
The three packages containing powder were from Spain. The package 
containing tablets were sent from United Kingdom.
United Kingdom




Confirmed as 5-IT succinate by NMR.
May 2012 Pale brown powder 
containing succinate salt




Product label stated ‘5-IT’ ‘500mg’ ‘NOT FOR HUMAN 
CONSUMPTION’.
Analysis by GCMS. Molecular formula confirmed by High Res MS. 
Confirmed as 5-IT succinate by proton NMR.













09/06/2012 One seizure of 116 




During the police investigation of one of the fatal cases from the 
United Kingdom where the presence of 5-IT was confirmed, the police 
were informed that the product consumed by the deceased had been 
purchased at a ‘headshop’ in Edinburgh. Police executed a search 
warrant at the Edinburgh premises and recovered a large quantity of 
items (160 productions) including bulk quantities of powders, herbal 
material and packaged products.
One of the items submitted to the Forensic Science Laboratory contained 
116 yellow packages labelled ‘Benzofury’ with a graphic displaying 
the structure of 5-APB. Four of these packages, selected at random, were 
examined and each found to contain a single blue unmarked biconvex 
tablet which were each analysed and found to contain 5-IT.
Other items of interest recovered from the ‘headshop’ were: Yellow 
capsules labelled ‘benzofury’ found to contain brown powder containing 
5/6-APB. 31 g of brown powder found to contain 5/6-APB. 174 
packages (98 of one type and 76 of a second type) each containing 1 
g of crystalline substance identified as methylthienylpropamine (MPA).
08/09/2012 One seizure of seven 
red and white gelatine 
capsules with no markings 
on them. Also contained 
diphenyl prolinol (D2PM).
Customs Guernsey The Guernsey Border Agency seized the capsules along with a number 
of Class B substances from a person arriving on the Island. Analysis was 
carried out by the Guernsey States Analyst.
Norway
17/04/2012 One seizure of 1 g in a 
small bag with zip-lock 
Customs Gardermoen, 
Oslo Airport
Identified with MS only.
* The Forensic Institute of the National Tax and Customs Administration of Hungary reported 0 seizures of 5-IT.
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Annex 3 — Deaths associated with 5-(2-aminopropyl)indole (5-IT) reported to the EMCDDA
Country Date of death 5-(2-aminopropyl)indole (mg/L) in blood Other substances present Notes
Hungary 12 April 2012 Not determined
34 microg/ml (blood)
(the toxicological examination identified it as 
AMT based on GC-MS, while the substance 
found next to the bodies was finally confirmed to 
be 5-(2-aminopropyl)indole by FTIR and NMR)
Not specified 40 year old male found dead in his flat beside 
his companion. No signs of forcible entry in the 
room or external injuries on the body. Signs of 
long sexual intercourse, extreme hyperthermia 
and the use of psychoactive substances.
Cause of death ‘Circulatory failure and 
respiratory failure were the direct causes of 
death that were the results of 5-IT intoxication.’
Hungary 12 April 2012 Not determined
84 mikrog/ml (blood)
(the toxicological examination identified it as 
AMT based on GC-MS, while the substance 
found next to the bodies was finally confirmed to 
be 5-(2-aminopropyl)indole by FTIR and NMR)
Not specified 35 year old female found dead in her flat 
beside her companion. No signs of forcible 
entry in the room. Some external injuries (due to 
faint/fall) but no sign of violence. Signs of long 
sexual intercourse, extreme hyperthermia and the 
use of psychoactive substances.
Cause of death ‘Circulatory failure and 
respiratory failure were the direct causes of 
death that were the results of 5-IT intoxication.’
Sweden 
15 deaths
April – June 2012 0.7 to 5.2 microg/mL blood
In one case 18.6 microg/mL blood
In two cases, 5-(2-aminopropyl)indole was the 
only substance found and in the other cases, it 
was found in combination with pharmaceuticals 
or other drugs (not specified)
All of the deceased were men, 13 of whom 
were aged 20-30 years, the remaining two 
were over 30.
In 14 of the cases the cause of death is 
considered to be related to 5-(2-aminopropyl)
indole and in the remaining case the cause was 
disease.
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Country Date of death 5-(2-aminopropyl)indole (mg/L) in blood Other substances present Notes
United Kingdom June 2012 0.379 mg/L 5-APB (0.016 mg/L), 6-APB (0.057 mg/L), 
diazepam (0.037 mg/L), nordiazepam (0.009 
mg/L), temazepam (0.001 mg/L) and AMT 
(less than 0.01 mg/L). Urine analysis detected 
amphetamine, 5-(2- aminopropyl)indole, 5-APB, 
6-APB, AMT and benzodiazepines. In addition, 
5-(2- aminopropyl)indole, 5-APB, 6-APB, AMT 
and diazepam were detected in the stomach 
contents.
Cause of death was ‘fatality following the 
ingestion of ‘Benzo Fury’’ and certified as ‘5-(2- 
aminopropyl)indole (5-API; 5-IT) and Benzofuran 
toxicity’
United Kingdom June 2012 0.300 mg/L in post-mortem blood and 
approximately 0.513 mg/L in ante-mortem 
blood
MDMA (0.468 mg/L ante-mortem blood, 
0.502 mg/L post-mortem blood), MDA (0.036 
mg/L ante-mortem blood, 0.046 mg/L post-
mortem blood), 6-APB (0.005 mg/L post-mortem 
blood only), atropine and lignocaine.
It was noted that there was a high concentration 
of MDMA, which in isolation was considered 
to be at a fatal level however, a cumulative/
synergistic effect of 5-(2-aminopropyl)indole 
was not excluded and the cause of death was 
recorded as ‘multidrug toxicity’.
United Kingdom  
2 deaths
Not known Not specified 5-/6-APB in one case and other drugs (not 
specified)
In a letter to the British Medical Journal the 
authors from Centre for Forensic and Legal 
Medicine, University of Dundee, United 
Kingdom ‘identified 5-IT in postmortem blood 
samples of two young adults.’ Further details 
were not available.
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